hero image
Scott Requadt - Consulate General of Canada (CTA Boston). Boston, MA, US

Scott Requadt Scott Requadt

CEO | Talaris Therapeutics


Scott Requadt has operating and investment experience in the biopharmaceutical industry including therapeutics, medtech and diagnostics.



Scott Requadt, JD, MBA, is the CEO of Talaris Therapeutics and serves on the Board of Directors. Scott has over 17 years of operating and investment experience in the biopharmaceutical industry. Scott was previously a Managing Director of Clarus (now Blackstone Life Sciences), where he sourced, led and managed multiple investments for Clarus spanning therapeutics, medtech and diagnostics. He currently serves on the Board of Directors of ESSA Pharmaceuticals (Nasdaq: EPIX), and previously served on the Boards of Edev S.a.r.l., Avrobio (Nasdaq: AVRO), VBI Vaccines (Nasdaq: VBIV) and TyRx, Inc. Scott remains a Venture Partner advisor to Blackstone Life Sciences. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. Prior to TransForm, Scott was an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University (First Class Honors), a J.D. from University of Toronto and an MBA from Harvard Business School, where he was a Baker Scholar.

Industry Expertise (2)



Areas of Expertise (6)


Corporate Development

Life Sciences


Venture Capital

Pharmaceutical Industry

Education (3)

Harvard Business School: M.B.A., Business Administration 2001

University of Toronto Law School: L.L.B. 1993

McGill University: B.Comm, Economics & Finance 1990





loading image


Talaris Therapeutics


Selected Media Appearances (3)

Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients

Business Wire  online


“Living donor kidney transplants save lives. However, they have a downside: the lifelong regimen of immunosuppressive drugs that organ transplant recipients must take elevates their risks of hypertension, high cholesterol, type 2 diabetes, sleep and CNS disorders, infections and certain cancers. Moreover, immunosuppressive drugs are, themselves, toxic to the kidney, leading to declining kidney function over time. On average, a transplanted kidney only lasts between 12-15 years, and many kidney transplant recipients will require multiple transplants over their lifetime,” said Scott Requadt, Chief Executive Officer of Talaris. “In our Phase 2 clinical trial, FCR001 demonstrated the capability to durably free a high percentage of LDKT recipients from immunosuppression and improve their overall quality of life post-transplant, findings which we now hope to reproduce in a larger group of patients in this Phase 3 trial as we advance this potentially transformative therapy...”

view more

FDA approves next phase of medical breakthrough in kidney transplants

WDRB  online


Scott Requadt, the company's CEO, said that patients who started Talaris' trial 10 years ago have not had to take immunosuppessants the entire time...

view more

Investigational Cell Therapy FCR001 Shows Promise for Preventing Post-transplant Kidney Failure

Alport Syndrome News  online


“We’re very excited by this demonstration of the potential of FCR001 to durably reset the immune system and halt autoimmune disease in patients in our Phase 2 trial. Many autoimmune diseases of the kidney are not resolved by a conventional kidney transplant, and therefore patients may require multiple transplants over the course of their lives. We’re hopeful that our cell therapy could interrupt this cycle of repeat transplants,” Scott Requadt, Talaris’ CEO, said in a press release...

view more